Lianpan Dai

Chinese Academy of Sciences — China

Medicine · Health Sciences

27h-index5.0kcitations81works9.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(47), COVID-19 Clinical Research Studies(16), Mosquito-borne diseases and control(15), Immunotherapy and Immune Responses(13), Viral Infections and Vectors(13)

Publications81 total

Engineered internal architecture of core-shell lipid nanoparticles promotes efficient mRNA endosomal release
Nature Communications·2026Open Access
Pulmonary Surfactant Protein-Hitchhiking Inhalable Vaccines Augment Mucosal and Systemic Antiviral Immunity
ACS Nano·2025· 1 cited
Multivalent mpox protein nanoparticle vaccines confer cross-protection against orthopoxvirus infection
PLoS Pathogens·2025· 2 citedOpen Access
A SARS‐CoV and SARS‐CoV‐2 RBD Heterodimer Vaccine Candidate
Journal of Medical Virology·2025· 1 citedOpen Access
Neutralization of SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 by human and murine sera
npj Vaccines·2024· 18 citedOpen Access
Protective RBD-dimer vaccines against SARS-CoV-2 and its variants produced in glycoengineered Pichia pastoris
PLoS Pathogens·2024· 6 citedOpen Access
Approach from the laboratory to the field: New strategies in the control of mosquito-borne infectious diseases
Science China Life Sciences·2024· 3 cited
Mosaic RBD nanoparticle elicits immunodominant antibody responses across sarbecoviruses
Cell Reports·2024· 18 citedOpen Access
Injectable Hydrogel Mucosal Vaccine Elicits Protective Immunity against Respiratory Viruses
ACS Nano·2024· 32 cited
Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies
Med·2024· 19 cited
Safety and immunogenicity of COVID-19 vaccine ZF2001 in Chinese aged 60 years and older
hLife·2024· 7 citedOpen Access
Correction: Durable and enhanced immunity against SARS-CoV-2 elicited by manganese nanoadjuvant formulated subunit vaccine
Signal Transduction and Targeted Therapy·2024· 1 citedOpen Access
Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2
Proceedings of the National Academy of Sciences·2023· 33 citedOpen Access
Durable and enhanced immunity against SARS-CoV-2 elicited by manganese nanoadjuvant formulated subunit vaccine
Signal Transduction and Targeted Therapy·2023· 20 citedOpen Access
A head-to-head comparative study on the immunogenicity of three platforms of COVID-19 Delta-Omicron chimeric RBD-dimer vaccines
Chinese Science Bulletin (Chinese Version)·2023· 2 citedOpen Access
Spatially resolved transcriptomics reveals distinct pulmonary immune responses during influenza virus and SARS-CoV-2 infections
Science Bulletin·2023· 9 citedOpen Access
A protective human antibody against respiratory syncytial virus by targeting a prefusion epitope across sites IV and V of the viral fusion glycoprotein
hLife·2023· 13 citedOpen Access
SARS-CoV-2 Omicron BA.2.86: less neutralization evasion compared to XBB sub-variants
2023· 6 citedOpen Access
Broad protective RBD heterotrimer vaccines neutralize SARS-CoV-2 including Omicron sub-variants XBB/BQ.1.1/BF.7
PLoS Pathogens·2023· 15 citedOpen Access
Neutralization of SARS-CoV-2 EG.5/EG.5.1 by sera from ZF2001 RBD-dimer and its next-generation vaccines
2023· 4 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

George F. Gao(40), Kun Xu(20), Jinghua Yan(17), Yaling An(14), Xin Zhao(13), Jianxun Qi(10), Yi Shi(10), Qihui Wang(10), Yuhai Bi(9), Tianyi Zheng(7), Shihua Li(7), Senyu Xu(7), Yuxuan Han(6), Enqi Huang(5), Yan Li(5), Gary Wong(5), Jian Song(5), Shilong Yang(5), Changwei W. Wu(5), Zhongyu Hu(5)